All posts by PIER MARIA FORNASARI

PIER MARIA FORNASARI
2022-05-30

Study: Patients with severe COVID-19 pneumonia treated with leukotriene inhibitors are more likely to survive, University of Buffalo researchers find

In a retrospective study based on big data, the researchers found that Leukotriene Inhibitors (LTI)s prevented death in COVID-19 patients with low oxygen saturation University at Buffalo biomedical informatics researchers have found that patients hospitalized with COVID-19 pneumonia had a 13.5% survival advantage when treated with a combination of leukotriene inhibitors (LTIs) and the steroid

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-05-21

‘Cell pores’ discovery and a new drug give hope to millions of brain and spinal cord injury patients

Scientists from the University of Birmingham have shown an existing drug may reduce damage after spinal cord injury, by blocking the inflammatory response in the spinal cord. Their research, published today in Clinical and Translational Medicine, demonstrates that AZD1236, a drug developed by AstraZeneca, can significantly reduce “secondary damage” caused by the body’s response to spinal

Read More

No Comments InBRAIN
PIER MARIA FORNASARI
2022-05-21

Amyloid production induced by neutrophil elastase as possible mechanism behind enigmatic symptoms in Severe Covid-19

In severe covid-19 and long-term covid, disorders of blood coagulation often occur. Now, researchers at LiU have discovered that the body’s immune system can affect the nail protein on the surface of the sars-cov-2 virus so that it forms misfolded protein, so-called amyloid. The findings point to a possible link between harmful amyloid formation and covid-19 symptoms.

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-05-21

BWH Scientists Develop ‘Off the Shelf’ Engineered Stem Cells to Treat Aggressive Glioblastoma

Glioblastomas (GBMs) are highly aggressive cancerous tumors of the brain and spinal cord. Brain cancers like GBM are challenging to treat because many cancer therapeutics cannot pass through the blood-brain barrier, and more than 90 percent of GBM tumors return after being surgically removed, despite surgery and subsequent chemo- and radiation therapy being the most

Read More

No Comments InCANCER
PIER MARIA FORNASARI
2022-05-19

University of Minnesota technology allows amputees to control a robotic arm with their mind

Research team makes mind-reading possible with electronics and AI University of Minnesota Twin Cities researchers have developed a more accurate, less invasive technology that allows amputees to move a robotic arm using their brain signals instead of their muscles.  Many current commercial prosthetic limbs use a cable and harness system that is controlled by the

Read More

No Comments InPROSTHETIC LIMB
PIER MARIA FORNASARI
2022-05-19

90-Day Clinical Outcome of Critically Ill Hospitalized Covid-19 Patients Treated with Imatinib: lower mortality rate, shorter duration of invasive ventilation and more ventilator free days.

Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference. The study investigated the long-term efficacy of imatinib in hospitalized COVID-19 patients in the Netherlands as part of the randomized, double-blind, placebo-controlled CounterCOVID study. A tyrosine kinase inhibitor, imatinib is currently an oncology

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2022-05-17

Identifying who has long COVID in the USA: a machine learning approach using N3C data

Using machine learning, researchers find patterns in electronic health record data to better identify those likely to have the condition. Long COVID is marked by wide-ranging symptoms, including shortness of breath, fatigue, fever, headaches, “brain fog” and other neurological problems. Such symptoms can last for many months or longer after an initial COVID-19 diagnosis. One

Read More

No Comments InCovid-19